Stocks and Investing
Stocks and Investing
Wed, April 10, 2024
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
[ Wed, Apr 10th 2024
] - WOPRAI
Charles Duncan Reiterated (ACAD) at Buy and Held Target at $37 on, Apr 10th, 2024
Charles Duncan of Cantor Fitzgerald, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $37 on, Apr 10th, 2024.
Charles has made no other calls on ACAD in the last 4 months.
There are 15 other peers that have a rating on ACAD. Out of the 15 peers that are also analyzing ACAD, 5 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, March 12th, 2024
- Uy Ear of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, March 12th, 2024
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
- Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023
These are the ratings of the 10 analyists that currently disagree with Charles
- Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $32 on, Tuesday, April 9th, 2024
- Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $25 on, Monday, March 25th, 2024
- Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Decreased Target to $30 on, Wednesday, March 13th, 2024
- Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $31 on, Tuesday, March 12th, 2024
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Tuesday, March 12th, 2024
- David Hoang of "Citigroup" Maintained at Strong Buy with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $39 on, Tuesday, March 12th, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $33 on, Tuesday, March 12th, 2024
- Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
Contributing Sources